DUBLIN–(BUSINESS WIRE)–The “Crigler-Najjar
Syndrome – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.
Crigler-Najjar Syndrome – Pipeline Review, H1 2019, provides an overview
of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape.
Crigler-Najjar syndrome is a severe condition characterized by high
levels of a toxic substance called bilirubin in the blood
(hyperbilirubinemia). Symptoms include yellow skin (jaundice) and yellow
in the whites of the eyes (icterus). It occurs when the enzyme that
normally converts bilirubin into a form that can easily be removed from
the body does not work correctly. Treatment includes phototherapy, liver
transplantation and blood transfusions.
This latest pipeline guide Crigler-Najjar Syndrome – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Crigler-Najjar Syndrome (Genetic Disorders), complete
with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Crigler-Najjar Syndrome and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
II, Preclinical and Discovery stages are 2, 2 and 1 respectively.
Similarly, the Universities portfolio in Phase II stages comprises 1
Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic
landscape of Crigler-Najjar Syndrome (Genetic Disorders).
The pipeline guide reviews pipeline therapeutics for Crigler-Najjar
Syndrome (Genetic Disorders) by companies and universities/research
institutes based on information derived from company and
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
The pipeline guide reviews key companies involved in Crigler-Najjar
Syndrome (Genetic Disorders) therapeutics and enlists all their major
and minor projects.
The pipeline guide evaluates Crigler-Najjar Syndrome (Genetic
Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
The pipeline guide reviews latest news related to pipeline
therapeutics for Crigler-Najjar Syndrome (Genetic Disorders)
Reasons to Buy
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under
development for Crigler-Najjar Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding
Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus
of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
- Audentes Therapeutics Inc
- International Stem Cell Corp
- Logicbio Therapeutics Inc
- Promethera Biosciences SA
- Selecta Biosciences Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/swc8l3
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
and Metabolic Disorders Drugs